QL1706

ApprovedSmall molecule

Qilu Pharmaceutical Co., Ltd.

QL1706 is one of 357 small molecule programs targeting Esophageal Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

356

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Intrahepatic CholangiocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

Esophageal CarcinomaPhase 1/Phase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Intrahepatic CholangiocarcinomaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

QL1706

Qilu Pharmaceutical Co., Ltd.

Approved

5 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Adenocard

Astellas

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Avastin

Roche

Preclinical

4 9

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 10

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Not yet recruiting

Hepatocellular Carcinoma

NCT06822985

Q4 2026

Phase 2Recruiting

First-Line

NCT06313970

Phase 2Not yet recruiting

First-Line Treatment

NCT06750861

Q2 2027

Phase 2Recruiting

Resectable NSCLC

NCT06897046

Q3 2027

Phase 2Recruiting

Intrahepatic Cholangiocarcinoma

NCT07070700

Phase 1/2Not yet recruiting

Esophageal Carcinoma

NCT06746961

Clinical

Trials by Indication[1]

Cervical Cancer5 trials

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT05179317·60 enrolled

SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07256236·89 enrolled

A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT05557565·150 enrolled

Show 2 more trials

QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07141186·50 enrolled

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05446883·498 enrolled

Breast Cancer5 trials

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

Not yet recruiting·—·Phase 2·NCT07413601·78 enrolled

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

Recruiting·HHenan Cancer Hospital·Phase 2·NCT06967103·238 enrolled

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Recruiting·WWenjin Yin·Phase 2·NCT07180160·123 enrolled

Show 2 more trials

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06404463·76 enrolled

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07246317·188 enrolled

Hepatocellular Carcinoma5 trials

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2/3·NCT05976568·668 enrolled

QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma

Not yet recruiting·WWan-Guang Zhang·Phase 1·NCT06822985·21 enrolled

A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1/2·NCT05603039·80 enrolled

Show 2 more trials

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

Not yet recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT07179900·60 enrolled

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting·NNanjing Tianyinshan Hospital·N/A·NCT06893887·300 enrolled

Non-Small Cell Lung Cancer3 trials

A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT05329025·100 enrolled

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05487391·632 enrolled

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Active, not recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05690945·606 enrolled

First-line Treatment2 trials

QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT05799820·60 enrolled

QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC

Not yet recruiting·—·Phase 2·NCT06750861·30 enrolled

29 more indications

Small Cell Lung Cancer2 trials

A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Active, not recruiting·SShanghai Chest Hospital·Phase 2·NCT07091305·28 enrolled

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Completed· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT05309629·40 enrolled

Nasopharyngeal Carcinoma2 trials

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Recruiting·SSun Yat-Sen University Cancer Center·Phase 3·NCT06749899·580 enrolled

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2/3·NCT05576272·460 enrolled

Non-squamous NSCLC1 trial

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Not yet recruiting·GGuangdong Association of Clinical Trials·Phase 2·NCT07416058·61 enrolled

Advanced Malignant Solid Tumors1 trial

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT06446388·360 enrolled

Liver Metastases1 trial

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

Recruiting·FFujian Cancer Hospital·Phase 2·NCT06787183·42 enrolled

Unresectable1 trial

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

Not yet recruiting·QQianfoshan Hospital·Phase 2·NCT07009145·22 enrolled

Metastatic Colorectal Cancer1 trial

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07025239·430 enrolled

Biliary Tract Tumors1 trial

QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors

Recruiting·—·Phase 2·NCT06892925·59 enrolled

Stage III Colon Cancer1 trial

QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

Not yet recruiting·QQilu Hospital of Shandong University·Phase 2·NCT07156682·21 enrolled

Chemotherapy1 trial

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Recruiting·FFudan University·Phase 2·NCT06786026·60 enrolled

Phase II1 trial

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05490719·39 enrolled

Ovarian Cancer1 trial

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Not yet recruiting·WWest China Second University Hospital·Phase 2·NCT06509971·39 enrolled

Resectable NSCLC1 trial

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Recruiting·—·Phase 2·NCT06897046·90 enrolled

Colon Cancer1 trial

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT06686576·363 enrolled

Tuvonralimab1 trial

Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

Recruiting·PPeking Union Medical College Hospital·Phase 1/2·NCT06941766·20 enrolled

Malignant Tumor1 trial

A Study of QL1706 in Subjects With Advanced Malignant Tumor

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1·NCT04296994·99 enrolled

Patients With Solid Tumors1 trial

A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1·NCT05171790·419 enrolled

Soft Tissue Sarcoma1 trial

QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06939855·45 enrolled

Gastric Cancer1 trial

QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07315035·74 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Recruiting·FFudan University·Phase 2·NCT07070700·56 enrolled

Treatment1 trial

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

Recruiting·XXijing Hospital·Phase 1·NCT07178171·30 enrolled

Esophageal Carcinoma1 trial

Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy

Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 1/2·NCT06746961·49 enrolled

Leptomeningeal Metastasis1 trial

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Recruiting·GGuangzhou Medical University·Phase 1/2·NCT06809530·34 enrolled

Ovarian Clear Cell Carcinoma1 trial

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Not yet recruiting·TTongji Hospital·Phase 3·NCT07002346·226 enrolled

Second-line Treatment1 trial

The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC

Not yet recruiting·QQilu Hospital of Shandong University·Phase 2·NCT07172217·33 enrolled

Pancreatic Cancer1 trial

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06951997·33 enrolled

First-line1 trial

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Recruiting·FFudan University·Phase 2·NCT06313970·58 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1/2·NCT07256782·444 enrolled

HCC - Hepatocellular Carcinoma1 trial

A Prospective, Single-Arm, Single-Center Exploratory Clinical Study of Stereotactic Body Radiation Therapy Combined With QL1706 in the Second-Line Treatment of Hepatocellular Carcinoma

Not yet recruiting·HHebei Medical University Fourth Hospital·Approved·NCT07668570·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 51 trial records for QL1706. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QL1706 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QL1706. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qilu Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Qilu Pharmaceutical Co., Ltd.

QL1706

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Cervical Cancer5 trials

Breast Cancer5 trials

Hepatocellular Carcinoma5 trials

Non-Small Cell Lung Cancer3 trials

First-line Treatment2 trials

Small Cell Lung Cancer2 trials

Nasopharyngeal Carcinoma2 trials

Non-squamous NSCLC1 trial

Advanced Malignant Solid Tumors1 trial

Liver Metastases1 trial

Unresectable1 trial

Metastatic Colorectal Cancer1 trial

Biliary Tract Tumors1 trial

Stage III Colon Cancer1 trial

Chemotherapy1 trial

Phase II1 trial

Ovarian Cancer1 trial

Resectable NSCLC1 trial

Colon Cancer1 trial

Tuvonralimab1 trial

Malignant Tumor1 trial

Patients With Solid Tumors1 trial

Soft Tissue Sarcoma1 trial

Gastric Cancer1 trial

Intrahepatic Cholangiocarcinoma1 trial

Treatment1 trial

Esophageal Carcinoma1 trial

Leptomeningeal Metastasis1 trial

Ovarian Clear Cell Carcinoma1 trial

Second-line Treatment1 trial

Pancreatic Cancer1 trial

First-line1 trial

Patients With Advanced Solid Tumors1 trial

HCC - Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News